These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 15964500

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
    Hubert D, Leroy S, Nove-Josserand R, Murris-Espin M, Mely L, Dominique S, Delaisi B, Kho P, Kovarik JM.
    J Cyst Fibros; 2009 Sep; 8(5):332-7. PubMed ID: 19651542
    [Abstract] [Full Text] [Related]

  • 24. Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment.
    MacLeod DL, Nelson LE, Shawar RM, Lin BB, Lockwood LG, Dirk JE, Miller GH, Burns JL, Garber RL.
    J Infect Dis; 2000 Mar; 181(3):1180-4. PubMed ID: 10720551
    [Abstract] [Full Text] [Related]

  • 25. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
    Ferroni A, Guillemot D, Moumile K, Bernede C, Le Bourgeois M, Waernessyckle S, Descamps P, Sermet-Gaudelus I, Lenoir G, Berche P, Taddei F.
    Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
    [Abstract] [Full Text] [Related]

  • 26. Recovery of antimicrobial-resistant Pseudomonas aeruginosa from sputa of cystic fibrosis patients by culture on selective media.
    Perry JD, Laine L, Hughes S, Nicholson A, Galloway A, Gould FK.
    J Antimicrob Chemother; 2008 May; 61(5):1057-61. PubMed ID: 18316821
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of the pharmacokinetics and pharmacodynamics of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infections using data from two phase 2 clinical studies.
    Okusanya OO, Bhavnani SM, Hammel JP, Forrest A, Bulik CC, Ambrose PG, Gupta R.
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5005-15. PubMed ID: 24687506
    [Abstract] [Full Text] [Related]

  • 28. Cytokine levels in sputum of cystic fibrosis patients before and after antibiotic therapy.
    Colombo C, Costantini D, Rocchi A, Cariani L, Garlaschi ML, Tirelli S, Calori G, Copreni E, Conese M.
    Pediatr Pulmonol; 2005 Jul; 40(1):15-21. PubMed ID: 15858808
    [Abstract] [Full Text] [Related]

  • 29. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model.
    Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH, Firsov AA.
    Int J Antimicrob Agents; 2007 Feb; 29(2):165-9. PubMed ID: 17207607
    [Abstract] [Full Text] [Related]

  • 30. Bicompartmental kinetics of tobramycin analysed with a wide range of covariates.
    Inclan G, Suarez E, Calvo R, Aguirre C, Macheras P, Gazouli M, Lukas JC.
    Int J Antimicrob Agents; 2005 Oct; 26(4):304-11. PubMed ID: 16168626
    [Abstract] [Full Text] [Related]

  • 31. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, Sardet A, Deschildre A, Druon D, Arrouet-Lagande C.
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [Abstract] [Full Text] [Related]

  • 32. Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters.
    Douchain F, Lebas L, Houdas S, Chivet C, Bakhache P, Pautard JC.
    Acta Univ Carol Med (Praha); 1990 Jun; 36(1-4):37-9. PubMed ID: 2130714
    [No Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J, Cranswick N.
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [Abstract] [Full Text] [Related]

  • 34. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
    Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK.
    Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
    [Abstract] [Full Text] [Related]

  • 35. In vitro interactions of tobramycin with various nonantibiotics against Pseudomonas aeruginosa and Burkholderia cenocepacia.
    Treerat P, Widmer F, Middleton PG, Iredell J, George AM.
    FEMS Microbiol Lett; 2008 Aug; 285(1):40-50. PubMed ID: 18513356
    [Abstract] [Full Text] [Related]

  • 36. Pharmacokinetic variability of extended interval tobramycin in burn patients.
    Bracco D, Landry C, Dubois MJ, Eggimann P.
    Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
    [Abstract] [Full Text] [Related]

  • 37. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C, Hall M, Conway S, Peckham D, Denton M.
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [Abstract] [Full Text] [Related]

  • 38. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, Elkins M, Thompson B, Macleod C, Aaron SD, Harbour C.
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [Abstract] [Full Text] [Related]

  • 39. [Detection and management of early Pseudomonas aeruginosa infection in patients with cystic fibrosis].
    Kernen Y, Sauty A, Roulet M.
    Rev Med Suisse; 2005 Mar 02; 1(9):637-8, 640. PubMed ID: 15813341
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.